Browse Articles

Discover research articles across all indexed journals

Evaluating the role of cancer-associated fibroblasts in T cell–mediated proinflammatory reprogramming of tumor associated macrophages in the prostate cancer tumor microenvironment.

Journal of Clinical Oncology David Kosoff, Erika Heninger, Matthew T Breneman et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.248

248 Background: Tumor-associated macrophages (TAMs) have been implicated as a critical mediator of T cell exclusion and inhibition within the prostate TME. However, using a microscale cell culture platform, known as Stacks, we have previously demonstrated that while prostate tumor cells induce an immunosuppressive phenotype in TAMs, activated T cells can reprogram these macrophages towards a proinflammatory phenotype that augments tumor-directed T cell responses. To investigate how other cell populations within the TME impact T cell mediated macrophage reprogramming, we expanded our models to include cancer-associated fibroblasts (CAFs), which have been previously shown to have immunosuppressive effects that regulate macrophage function in the TME. Methods: Primary T cells and autologous monocyte-derived macrophages (MDMs) were derived from the peripheral blood samples of patients receiving care at the University of Wisconsin Carbone Cancer Center and with William S Middleton Memorial Veterans Hospital in Madison, WI. MDMs were cultured with prostate tumor (22Rv1) and CAF (hPrCSC-44) cells in mono-, co-, and tri-culture models for 72h in the Stacks microfluidic cell culture platform. Activated autologous T cells were then added to each condition for an additional 24h of culture. Models were analyzed for T cell migration and surface marker expression by confocal microscopy, secreted cytokine and chemokine profiles by protein bead array, and gene expression by qRT-PCR. Results: We found that MDM-mediated augmentation of CD4 + and CD8+ T cell migration within the prostate TME models was abrogated in the presence of CAFs. Analysis of gene expression further demonstrated that the presence of CAFs in our quad culture models resulted in a decrease in expression of T cell recruitment chemokines by the MDMs, including CCL2, CCL5, CXCL9, CXCL10, and CXCL11, compared to MDM tri-culture with tumor cells and T cells. MDMs also expressed higher levels of IL-10 mRNA, a potent immune suppressive factor, when CAFs were present in the TME. Conclusions: Using microscale cell culture technologies, we provide the first direct evidence that CAFs inhibit T cell mediated proinflammatory reprogramming of MDMs in the prostate TME. Furthermore, we demonstrate that this inhibition of MDM reprogramming is associated with a decrease in tumor-directed T cell migration compared to MDM, tumor cell, and T cell tri-cultures. This data suggests that CAFs, through their effects on MDMs/TAMs, may be playing a vital role in the inhibition of tumor-directed T cell responses. The pathways that are mediating this effect therefore represent valuable therapeutic targets to augment immunotherapeutic efficacy in prostate cancer treatment.

GLP1R expression in prostate cancer patients and effects of GLP1R agonism on prostate cancer cells.

Journal of Clinical Oncology Jordan Vellky, Natalie Marie Reizine, Donald Vander Griend Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.182

182 Background: As a disease of aging, metabolic co-morbidities are managed concurrently with prostate cancer. Recent FDA approvals have launched widespread use of GLP1 receptor agonist semaglutide for Type II Diabetes Mellitus and obesity. Mechanistically, semaglutide primarily activates GLP1 receptors in the pancreas. However, GLP1R is also expressed in advanced prostate cancer tissues where GLP1 agonism could affect signaling and disease progression. Understanding the effects of semaglutide treatment in prostate cancer is critical to gain a complete picture of the systemic effects this drug and potentially expose additional contexts where semaglutide can be therapeutically valuable in this disease space. Methods: RNA-sequencing data was accessed from dbGaP (consolidated, n=664) and Gene Expression Omnibus (GSE204057, n=55) to assess GLP1R expression in prostate cancer patients. Bioinformatics analyses were utilized to identify signaling pathways associated with GLP1R expression. Proliferation, metabolism, and signaling after GLP1R agonism with semaglutide were assessed in vitro in prostate cancer cell line models using incucyte, Seahorse, and a kinase proteome profiler array. Results: We identified GLP1R expression in advanced prostate cancer samples including 145/310 (46.8%) of metastases, 59/115 (51.3%) of castration-resistant prostate cancer (CRPC), and 9/15 (60%) of neuroendocrine prostate cancer (NEPC), where it was associated with Notch and Hedgehog Signaling. Semaglutide treatment in pre-clinical prostate cancer models resulted in decreased cell proliferation, decreased glycolytic function, and decreased activation of kinase-mediated signaling. This overall suppression of signaling downstream of GLP1R is consistent with Gai-coupled GPCR signaling, which was confirmed using a cAMP assay. Interestingly, in a trans-differentiation model there was a significant negative correlation between GLP1R and AR expression. Further, proliferation of prostate cancer cells was significantly decreased with combination treatment of enzalutamide with semaglutide compared to either treatment alone. Conclusions: GLP1R was expressed in advanced prostate cancer patients and treatment with semaglutide suppressed growth, metabolism, and signaling. This is clinically significant due to concurrent treatment for metabolic co-morbidities in men with prostate cancer. Our preliminary data shows that co-targeting AR and GLP1R decreased cell growth, suggesting GLP1R agonism may be therapeutically useful in combination with androgen receptor antagonists in advanced prostate cancer.

Results from the prior treatment cohort of a phase I/II study of nivolumab and axitinib in patients with advanced renal cell carcinoma.

Journal of Clinical Oncology Matthew R. Zibelman, Yasser Ged, Michael A Carducci et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.548

548 Background: Combination tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (IO) are an established standard of care for patients with metastatic renal cell carcinoma (mRCC). We report updated analysis of a multi-center, investigator-initiated (IIT), phase I/II study of axitinib (axi) with nivolumab (nivo) in the previously treated patient cohort. Methods: The study investigated the combination of axi/nivo in an initial dose finding phase I portion and a phase II portion including 2 parallel arms: treatment naïve mRCC patients and mRCC patients previously treated with TKIs or IO/IO combination (NCT03172754). We are presenting final results from the previously treated cohort. Included patients had pathology with any clear cell component, ECOG performance status of 0-1, no known or symptomatic brain metastases, and no history of autoimmune disease. The recommended phase 2 dose of axi was 5 mg BID and patients were treated for up to 2 years then could stop one or both therapies. The primary endpoint of the phase II portion was objective response rate (ORR) per investigator assessment. Results: Twenty-six patients were accrued to the previously treated arm, all evaluable for efficacy and toxicity. The median age was 62 yrs (range: 42-81), 80.8% were male and 88.5% were white. Twenty pts had 1 prior line of therapy (18 TKI alone), 6 pts had 2 or more prior lines of Tx. Two pts had prior nivo with ipilimumab. Median follow-up was 47.2 months. The ORR was 30.8% (all PRs) and 57.7% achieved stable disease. The primary PD rate was 11.5%. Median OS was 48.4 months and median PFS was 13.0 months. Six pts (23.1%) completed two years of Tx on trial and elected to stop one or both drugs (2 elected to stay on axi alone). Five pts remain progression-free and have received no subsequent therapy with a median progression-free interval of 23.2 months. None had received prior IO. Adverse event (AE) data was similar to published data for IO/TKI combinations. There was one Gr4 TRAE of elevated lipase and 12 pts (46%) experienced a Gr3 TRAE. One pt (4%) discontinued the study due to TRAEs. Conclusions: Final results from the previously treated cohort of this IIT of axi/nivo for pts with mRCC demonstrated an ORR of 30.8% and a DCR of 88.5% with no unexpected AEs. Though there were no CRs, disease control rate and median OS were encouraging in this previously treated population. This is the only reported IO/TKI trial that allowed for stopping of all Tx at 2 years, with 6 pts (23.1%) meeting this milestone, 5 of whom (19% of all pts) remain progression-free for a median period close to 2 years. Clinical trial information: NCT03172754 .

The prognostic role of circulating tumor DNA (ctDNA) clearance as a biomarker in localized and metastatic renal cell carcinoma (RCC): A single-center experience.

Journal of Clinical Oncology Adanma Ayanambakkam, Bibi Maryam, Priyanka Vallabhaneni et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.570

570 Background: The use of ctDNA-based molecular residual disease detection represents a promising prognostic biomarker in multiple solid tumors, yet limited data exist in RCC. This study aims to prospectively assess the utility of longitudinal ctDNA monitoring in localized and metastatic RCC. Methods: We conducted a retrospective analysis on the use of longitudinal ctDNA testing in a single academic center for patients with RCC from 2022 - 2024. We used a clinically validated, personalized, tumor-informed, multiple PCR-NGS assay (Signatera, Natera, Inc.) to detect and quantify ctDNA. A total of 229 plasma samples from 69 patients were analyzed. Clinical data were collected on pathologic subtype, tumor stage and grade including the presence of sarcomatoid/rhabdoid features and type of treatment. ctDNA dynamics were categorized as follows : clearance, decrease, or increase in ctDNA levels. Treating physicians were not blinded to ctDNA results, no treatment decisions were made based on ctDNA dynamics. Results: A total of 69 patients (mean age=62, 23% female) with RCC were included in the analysis, (median: 3 samples/patient), with 33 (48%) having localized RCC and 36 (52%) having metastatic RCC (mRCC). Clear cell RCC was the predominant subtype, present in 61 (88%) patients. Among 33 patients with localized disease, 8 (24%) patients were on surveillance, and 25 (76%) patients received adjuvant pembrolizumab. Among 36 patients with mRCC, 32 (89%) patients were on systemic therapy and 4 (11%) patients were on surveillance. Among those with localized RCC, 1 (3%) patient was ctDNA positive 12 months after nephrectomy and, subsequently developed metastatic disease 1 month from ctDNA detection. Thirty-two (97%) patients with localized RCC and ctDNA negative results remained relapse-free with a median follow-up of 9 months. Among patients with mRCC, 22 (61%) patients were ctDNA positive, 12 (55%) achieved ctDNA clearance (10 after systemic therapy and 2 spontaneously on surveillance). Of these, 10 (83%) remained progression-free at a median follow-up of 11.5 months, while 2 had rise in ctDNA levels after clearance, correlating with disease progression. At median follow-up of 15 months (range 2 to 70 months), all 4 patients with radiographic progression had rising ctDNA levels (median lead time 4 weeks). One patient had rising ctDNA without evidence of radiographic progression. Conclusions: Our findings highlight the potential of ctDNA detection and dynamics as a valuable prognostic biomarker for patients with both localized and metastatic RCC. These results support further prospective studies to establish the clinical utility of ctDNA clearance as a predictive marker in metastatic RCC.

Fiber-tip photothermal transducer with gold-coated multi-beam interferometric cavity for high sensitivity gas detection

Applied Physics Letters Sixiang Ran, Wenjun Ni, Chunyong Yang et al. Feb 10, 2025 DOI: 10.1063/5.0240821

The power-boosted laser transmitted via a fiber tip sinusoidally excites the target trace molecules, generating a photothermal (PT) effect. The Gaussian-distributed plane wave heats the medium adjacent to the Fresnel reflection surface. Meanwhile, a continuous probe light traverses the heating field, and the periodic temperature change then modulates the phase of the probe light. A multi-beam interferometer formed by aligning the Fresnel reflection surface to a gold-coated high-reflection surface possesses high resolution and sensitivity, significantly enhancing the detection performance. A well-established theoretical model of instantaneous PT transduction and optical phase modulation is employed to obtain the optimized interferometric configuration. To validate the effective interferometric phase transformation within the cavity, a comparison is made between the simple silicon cavity and the gold-coated cavity. The limitation of detection of such extrinsic fiber-tip PT sensors indicates one magnitude lower as compared to the conventional PT interferometric gas sensor with such robust and compact sensing designs. This work lays a solid foundation for future research on gas laser phase modulators and nonlinear laser–matter interactions.

Identification and validation of diagnostic biomarkers for temporal lobe epilepsy related to ferroptosis and potential therapeutic targets

Scientific Reports Dai Shi, Jingxuan Li, Zhenpeng Niu et al. Feb 10, 2025 DOI: 10.1038/s41598-025-89390-6

Evaluation of time to metastasis (TTM) from prostatectomy and survival in patients (pts) with metachronous metastatic hormone-sensitive prostate cancer (mHSPC) receiving androgen deprivation therapy (ADT) intensification: A real-world study.

Journal of Clinical Oncology Nicolas Sayegh, Yeonjung Jo, Zeynep Irem Ozay et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.100

100 Background: Metachronous mHSPC is associated with improved outcomes compared to synchronous (de novo) mHSPC. However, there are limited data on the effect of TTM after radical prostatectomy in patients with metachronous mHSPC treated with systemic therapies. Our objective was to explore the association of TTM after prostatectomy with survival outcomes in a real-world population. Methods: In this IRB-approved retrospective study, eligibility criteria were: pts with metachronous mHSPC who underwent radical prostatectomy and were treated with ADT plus androgen receptor pathway inhibitor (ARPI). Metachronous disease was defined as the absence of metastatic disease within 90 days of initial prostate cancer diagnosis. TTM was defined from the time of prostatectomy to the time of initial metastatic diagnosis and was analyzed as a continuous variable, then categorized. Progression-free survival (PFS) was defined from the start of therapy for mHSPC to disease progression or death from any cause. Overall survival (OS) was defined from treatment initiation for mHSPC to death from any reason or censored at the last follow-up. Multivariable analyses for PFS and OS were performed using a Cox proportional hazards model, adjusting for disease volume (per CHAARTED criteria), Gleason score, log-transformed PSA, and age. Results: Overall, 186 pts with metachronous mHSPC who previously underwent prostatectomy were eligible and included. Pts with a Gleason score of ≥ 8 comprised 44% of the cohort and those with age ≥ 65 comprised 68% of the cohort. A high volume of disease was present in 34% of the pts. Overall, median TTM was 46 months. On univariate analysis, a longer TTM was not associated with improved PFS (HR 1.0, 95% CI 1.0-1.1, P=0.3) or OS (HR 1.0, 95% CI 1.0-1.1, P=0.8), and results were consistent on multivariate analysis. No PFS or OS benefit was observed in pts achieving a TTM ≥1, 2, 3, and 4 years respectively, versus those who do not (Table). Conclusions: A prolonged TTM is not associated with survival outcomes after onset of metachronous mHSPC in pts treated with ADT + ARPI. OS and PFS in the mHSPC setting appear to be independent of timing of metastatic disease post prostatectomy in this pt population. Univariate Multivariate HR (P-value) PFS OS PFS OS TTM Continuous 1.0 (0.3) 1.0 (0.8) 1.0 (0.5) 1.0 (0.4) TTM <1 vs ≥1 0.9 (0.7) 0.8 (0.6) 0.7 (0.5) 0.7(0.5) TTM <2 vs ≥2 0.9 (0.8) 0.9(0.7) 0.6 (0.3) 0.6 (0.3) TTM <3 vs ≥3 0.9 (0.5) 0.8 (0.6) 0.6 (0.2) 0.6 (0.2) TTM <4 vs ≥4 0.9 (0.7) 1.1 (0.7) 0.9 (0.7) 0.9 (0.7)

Utilizing ChatGPT for assessing disease volume in patients (pts) with metastatic prostate cancer (mPC).

Journal of Clinical Oncology Diya Garg, Micah Ostrowski, Ayana Srivastava et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.42

42 Background: Artificial intelligence (AI) has transformed many aspects of healthcare, particularly in medical imaging analysis. In mPC, accurate identification of bone metastases is crucial in guiding pt management. This proof-of-concept study explores the application of ChatGPT-4o, a multimodal, generative pre-trained transformer (large language model) with emerging image recognition capabilities, in diagnosing bone metastases from bone scans and determining disease volume in pts with mPC. Methods: In this IRB-approved, retrospective study, pts with newly diagnosed mPC and bone-predominant disease were randomly selected. Those who had previously received bone-protecting agents, chemotherapy, hormone therapy, or radiation therapy prior to the bone scan were excluded. Using CHAARTED criteria, high-volume versus low-volume bone disease was classified based on radiologist reports. The bone scan images were then uploaded to ChatGPT, which was instructed to act as a radiologist and asked to classify the disease volume. ChatGPT's classifications were compared to the radiologists’ findings by using Cohen’s Kappa test. Confusion’s matrix was used to represent the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of ChatGPT. Results: A total of 110 pts were selected, with a median age of 67 years (range: 44 to 89). The majority were Caucasian (98.2%). The median Gleason score was 9, and 77.3% of pts had de novo metastatic disease. The median PSA value at diagnosis was 35.2 ng/ml (range: 1-5843). High-volume disease was present in 52% of pts. ChatGPT's overall concordance with radiologists was 74% (Cohen's Kappa = 0.65). For high-volume disease, ChatGPT demonstrated a high sensitivity of 92.3% (48/52). However, it misclassified 45.8% of low-volume cases as high-volume (specificity: 54.2%). The PPV and NPV of ChatGPT were 68.6% and 86.7%, respectively. Interestingly, ChatGPT’s accuracy was significantly higher when each case was analyzed individually (77.7%) compared to when cases were grouped in a single conversation (43.5%, p<0.001). Conclusions: This hypothesis-driven research demonstrated that ChatGPT-4o has the potential to read medical images independently and apply existing knowledge, such as the CHAARTED criteria, to assist in content generation. However, its reliability remains a significant challenge for broader use in healthcare. Notably, it exhibited "information fatigue," where accuracy significantly declined when similar or repetitive information accumulated within a single conversation.

Assessing genomic instability (GI) by shallow whole-genome sequencing (sWGS) to predict PARP inhibitor (PARPi) response in metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology Peter Slootbeek, Yarah M. Quint, Julian J.R. Kokke et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.194

194 Background: The heterogeneous efficacy of PARPi in patients with mCRPC and homologous recombination deficiency (HRd)-associated genetic alterations has emphasized the need for a more accurate selection of responding patients. sWGS offers a cost-effective method to identify HRd through GI analysis. However, the correlation between GI from sWGS and specific genotypes, along with its predictive value for PARPi response, remains unreported. Methods: A total of 289 samples from 267 patients were analyzed for GI by sWGS. Of these, 121 were newly sequenced with a mean depth of 2.05x and 168 were in silico down-sampled to 2x. Eighty-four percent of the samples were collected in the CRPC setting. Copy number analysis was performed using iChorCNA with a 50 Kb window size, and multiple genome-wide copy number plots were generated per sample with varying tumor content and ploidy. Two researchers independently selected the optimal plot, with discordant cases reviewed by a third, to quantify large-scale transitions and telomeric allelic imbalances per sample, which together constituted an adjusted GI score (aGIS). Results: The median aGIS of all samples was 21 (interquartile range [IQR] 16 – 30). Samples with HRd-associated genetic alterations (43%) had a higher median aGIS (26) than to those without (19, P < 0.0001). Deleterious aberrations in PALB2 resulted in the highest aGIS, followed by BRCA2 and ATM . The aGIS for genotypes with >3 samples are detailed (Table). Out of the 267 patients, 71 received PARPi. Their median aGIS was 27 (IQR: 19–37). The 33 patients with ≥50% PSA decline had a higher aGIS than the 37 without (aGIS 35 vs 22, P = 0.0001). In 60 patients with radiologic assessment, 22 had a partial response, 27 stable disease, and 11 progressive disease. The median aGIS for these groups were 32 (IQR: 25.5–49), 26 (IQR: 17.5–35), and 21 (IQR: 16.5–26.5), respectively, with a significant difference between partial and progressive disease (P = 0.0053). The Cox proportional hazards model did not show a significant effect of aGIS on progression-free survival (P = 0.144). Still, patients with the highest 25% aGIS had a median progression-free survival of 11 months, compared to 4 months for the lowest 25%, and 8 months for the remaining. Conclusions: The quantity of large-scale transitions and telomeric allelic imbalances, from sWGS, correlates with HRd-associated genetic alterations. In PARPi-treated patients, this aGIS is significantly associated with biochemical and radiologic response, even after selection by genotyping. These findings support the development of an sWGS-adjusted GI score for predicting PARPi response in mCRPC. Aberration in: N Median aGIS (IQR) PALB2 4 30.5 (15 – 44.75) BRCA2 50 29 (22 – 38.75) ATM 37 28 (20 – 34) BARD1 4 26.5 (15.5 – 34.5) RAD51B 5 26 (25 – 26) CDK12 20 18.5 (10.75 – 20.25) CHEK2 5 16 (12 – 17)

Real-world treatment patterns in patients diagnosed with metastatic castration-resistant prostate cancer in the US, 2018-2023.

Journal of Clinical Oncology Eleni Efstathiou, Weiyan Li, James Roose et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.74

74 Background: The treatment landscape in patients with metastatic castration-resistant prostate cancer (mCRPC) has evolved in recent years. This real-world study evaluates treatment patterns among a large contemporary cohort of patients with mCRPC in the US. Methods: This retrospective cohort study included patients with a confirmed mCRPC diagnosis from 1/1/2018 to 12/31/2023 in the US nationwide Flatiron Health electronic health record-derived deidentified database. Treatment patterns were evaluated by disease setting (metastatic hormone-sensitive prostate cancer [mHSPC], nonmetastatic castration-resistant prostate cancer [nmCRPC], mCRPC) and by use of androgen receptor pathway inhibitors (ARPI; abiraterone, enzalutamide, apalutamide, darolutamide) before mCRPC diagnosis. Patients were considered ARPI-experienced if they received at least 1 line of therapy (LOT) containing an ARPI before progressing to mCRPC. Patients were considered ARPI-naive otherwise. Results: Of 6301 patients with mCRPC (mean age, 75 years), 4915 (78%) received ≥1 LOT in the mCRPC setting. Among those with ≥1 LOT, 48% received second-line (2L) therapy. The most common first-line (1L) and 2L therapies in mCRPC were ARPI (1L, 75%; 2L, 55%) and chemotherapy (1L,16%; 2L, 33%). Most patients (4491, 71%) were ARPI-naive before mCRPC diagnosis. Among the 1810 (29%) patients who were ARPI-experienced before their mCRPC diagnosis, the median treatment duration with ARPI was 23 months. Use of ARPI in the mHSPC setting increased from 11% to 39% in patients diagnosed with mCRPC in 2018 and 2022, respectively. Similarly, in the nmCRPC setting, this figure rose from 20% to 39%. Consecutive use of ARPI in the mCRPC setting, with variations based on the year of mCRPC diagnosis, was observed in 54% to 65% of ARPI-naive patients and 31% to 48% of ARPI-experienced patients who received 1L ARPI and any 2L therapy. Use of chemotherapy increased from 13% to 19% in 1L and 29% to 40% in 2L in the mCRPC setting but decreased from 11% to 7% in mHSPC setting. Conclusions: In this community practice-based study, ARPI was the most common 1L and 2L therapy, followed by chemotherapy, in patients diagnosed with mCRPC from 2018 to 2023. Although ARPI use before mCRPC diagnosis has increased, more than two-thirds of patients overall remain ARPI-naive at mCRPC diagnosis. Despite not being recommended by guidelines, consecutive use of ARPI in the mCRPC setting was common in patients regardless of ARPI use before mCRPC diagnosis.

Anticathode effect on multimodal azimuthal oscillations in electron beam generated E×B plasma

Applied Physics Letters Nirbhav Singh Chopra, Yevgeny Raitses Feb 10, 2025 DOI: 10.1063/5.0252744

Electron beam (e-beam) generated plasmas with applied crossed electric and magnetic (E×B) fields are promising for low-damage (gentle) material processing. However, these plasmas can be subject to the formation of plasma non-uniformities propagating in the E×B direction. These rotating plasma structures (or “spokes”) enhance the transport of charged species across the magnetic field, which can harm the gentle processing capability of the plasma. In this work, we investigate the role of electrostatically active boundaries on the spoke formation by incorporating a variable bias conducting boundary (known as an anticathode) placed on the axially opposite side of the cathode. Our findings indicate azimuthal mode suppression occurs when the anticathode is electron collecting. Furthermore, we show selective azimuthal mode suppression by biasing the anticathode to an intermediate potential between the cathode and anode potentials. These findings suggest a link between the axial electron confinement in the e-beam generated plasma and azimuthally propagating plasma structure formation.

Male reproductive phenotype alterations in heterozygous β-globin gene knockout thalassemia (BKO) mice as a model for β-thalassemia patients

Scientific Reports Suparada Aiemongkot, Sukanya Ruschadaariyachat, Chinarat Changsangfa et al. Feb 10, 2025 DOI: 10.1038/s41598-025-87619-y

Impact of tumor burden on treatment patterns and outcomes in patients with locally advanced or metastatic urothelial carcinoma (la/mUC) treated with avelumab first-line maintenance (1LM).

Journal of Clinical Oncology Helen Moon, Mairead Kearney, Seyed Hamidreza Mahmoudpour et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.764

764 Background: With the evolving treatment (tx) landscape in la/mUC, patient (pt) clinical characteristics are increasingly important when selecting systemic anticancer tx. This study describes pt characteristics, tx patterns, and clinical outcomes by tumor burden in pts with la/mUC treated with avelumab 1LM following 1L platinum-based chemotherapy (PBC) with no progressive disease (PD). Methods: In this noninterventional retrospective study, pts with la/mUC were identified using Flatiron Health’s electronic health record database. Inclusion criteria were pts aged ≥18 years diagnosed with la/mUC between Jan 1, 2019, and Jul 31, 2023, treated with 1L PBC with no PD, followed by avelumab 1LM on/after Jul 1, 2020. Pt characteristics at 1LM initiation, tx patterns, and real-world overall response rate (rwORR) were reported using descriptive statistics. Real-world overall survival (rwOS), progression-free survival (rwPFS), time to next tx (TTNT), and time to tx discontinuation (TTD) were assessed using Kaplan-Meier methods. Subgroup analyses by disease burden were conducted reported: visceral (bone and other visceral) vs nonvisceral metastases (bone only) and lymph node only (includes distant lymph node) vs distant metastases. Results: Of 290 pts included, 156 (53.8%) were still receiving avelumab 1LM at data cutoff (Jul 31, 2023). Median age was 71 years; most pts were male (75.9%), White (70.7%), and had ECOG performance status 0/1 (78.3%). Median follow-up from 1LM initiation was 8.7 months. Among 266 pts with metastases, these were visceral in 142 (53.4%), nonvisceral in 124 (46.6%), distant in 183 (68.8%) and lymph node only in 83 (31.2%). 1L PBC was cisplatin-based in 52.4% and carboplatin-based in 47.6%. Median rwPFS and rwOS from avelumab 1LM initiation were 5.0 (95% CI, 3.9-5.8) and 22.0 (95% CI, 18.2-24.8) months, respectively. In pts with tumor assessment during avelumab 1LM (n=236), rwORR was 34.7%. Outcomes by disease burden are shown in the table. Conclusions: These results provide insights into clinical outcomes by tumor burden in pts with la/mUC treated with avelumab 1LM. Pts with nonvisceral and/or lymph node-only metastases had more favorable outcomes, consistent with the JAVELIN Bladder 100 trial. Outcome from 1LM start, median (95% CI), months Pts with metastases (n=266) Nonvisceral (n=124) Visceral (n=142) rwPFS 5.6 (4.1-7.8) 3.6 (3.1-5.0) rwOS 23.8 (15.4-NE) 19.1 (12.5-23.8) TTNT 6.6 (6.6-9.8) 6.0 (4.3-7.4) TTD 5.3 (4.2-10.1) 4.4 (3.5-5.7) Lymph node only (n=83) Distant (n=183) rwPFS 8.7 (5.0-NE) 3.6 (3.1-4.6) rwOS 24.3 (20.7-NE) 16.5 (12.5-22.6) TTNT 8.1 (6.2-23.8) 5.2 (4.3-6.7) TTD 10.1 (4.9-NE) 4.2 (3.3-5.5) NE, not estimable.

Impact of COVID-19 pandemic on the treatment of prostate cancer in Brazilian public health system, comparing pre and post pandemic data.

Journal of Clinical Oncology Gustavo Franco Carvalhal, Guilherme Augusto Zulli, Igor Alexandre Protzner Morbeck et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.373

373 Background: During the COVID-19 pandemic resources from the Brazilian Public Health System (BPHS) were directed to the treatment of COVID-19. The impact of the pandemic on the treatment of prostate cancer in Brazil has not yet been rigorously evaluated. Methods: We compared the number of radical prostatectomies (RP), radiotherapy (RT), and hormonal (HT) and chemotherapy (CT) treatments from March 1st, 2020 to February 29th, 2022, with that of the two pre-pandemic years (March 1st, 2018, to February 28th, 2020). Additionally, we evaluated the post-pandemic period from March 1st, 2022 to February 28th, 2024. A large proprietary healthcare data science platform offered by TECHTRIALS was surveyed. Results: In the pandemic, 15,364RPs were performed in the BPHS, (U$14,271,297); there was a 23.3% reduction in the number of surgeries compared with the pre-pandemic years: 19,778RPs, (U$18,056,470). In the post-pandemic years 18,716 RPs were performed (U$ 18,373,781.92), an increase of 21.8% in those treated by surgery. In the pandemic, 34,922 men received RT (U$39,616,736), a 18.7% reduction in the number of patients as compared with the two pre-pandemic years, when 42,614 men were treated (U$44,148,190). In the post-pandemic years, 43,142 men received RT, an increase of 19% compared to the pandemic years (U$48,870,739.03). Regarding HT, 116,490 men were treated during the pandemic (U$74,834,615); in the pre-pandemic, 115,949 patients received HT (U$75,179,674). In the post-pandemic years, 127,602 men were treated with HT (U$80,078,824), an increment of 6.5% in cost and 10% in the number of patients treated compared to the pandemic years. As to CT for hormone-resistant disease, in the pandemic period 14,946 men were treated (U$23,402,947) compared with 12,695 men treated in the two pre-pandemic years (U$19,239,099). In the post-pandemic years 18,850 men were treated (U$33.571.073,40) an increment of 48.4% in number of patients treated and with an increase of 74% in costs compared to the pandemic period. Conclusions: During the pandemic years, there was a significant reduction of potentially curative treatments for prostate cancer in the BPHS. The number of systemic therapies increased, probably reflecting the policy of maintaining systemic therapies active during the pandemic. In the post-pandemic years, there was an increase in the number of systemic treatments, while RT and RP returned to a state very close to their pre-pandemic numbers. The impact of the COVID-19 pandemic on prostate cancer mortality in Brazil remains speculative.

Efficacy and safety of SABR with TKI and IO therapy in patients with mRCC.

Journal of Clinical Oncology Kaiwei Yang, Mingwei Ma, Wei Yu et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.529

529 Background: Metastatic RCC is a deadly disease and TKI in combination with IO has become a standard therapy for most patients. But some of the pts may present with oligo-metastasis and some with meta site related symptoms. SABR (Stereotactic Ablative Body Radiotherapy) has been proved to be highly effective for RCC in some studies and with potential immune-enhancing ability. The purpose is to investigate the efficacy and safety of SABR with TKI and IO therapy in pts with mRCC. Methods: This is an ambispective cohort study including pts receiving SABR with TKI and IO at the same time. The primary endpoint was PFS. Secondary endpoints included OS, ORR, DCR and TTTC (Time to treatment change). We also analyzed some of the pts’ gene characteristics to investigate the relationship between gene alterations and prognosis. Adverse events were evaluated according to CTCAE 5.0. Results: Until Aug 2024, we retrospectively analyzed pts from Mar 2020 to Mar 2024, and prospectively from Mar 2024 to May 2024. A total of 79 pts were included, of whom 72.2% were with ccRCC, 68.4% were with oligo-metastases (≤5 meta sites), and 83.5% were combined with SABR before 1st-line systemic therapy failure. All pts were categorized to IMDC intermediate or poor prognosis group and TKI and IO combination was used in all pts. All pts with oligo-metastases received SABR for all tumor sites and others were for cytoreductive purpose.The median follow-up was 20.3 mo. The mPFS was 28.6 mo and TTTC was 31.8 mo. The ORR was 68.4% and the DCR was 89.9%. The DCR of radiation lesions was 96.2%. The mOS was 44.8 mo. For pts received SABR before or after 1 st -line systemic therapy failure, the mPFS were 30.6 mo vs. 9.6 mo, respectively (p=0.004). In addition, The NGS analysis was performed in 25 pts tumor samples. The most frequent genes mutated were VHL (60%), SETD2 (24%), ARID1A (24%), TP53 (20%), PTEN (20%), TEF3 (16%), BAP1 (12%), RET (12%), and PBRM1 (12%). We discovered a favorable trend in the prognosis for PFS in pts with tumors purely driven by VHL loss. Mutations in the mTOR pathway genes, PTEN and HRR-related genes appeared to lead to poorer PFS. However, due to limited sample size, statistical significance was not reached. Grade 3 or above AE was 50.2%, and there was no treatment-related death. Conclusions: Targeted therapy combined with immunotherapy and stereotactic radiotherapy has achieved satisfactory survival results for mRCC, and early intervention by SABR may lead to a better PFS. Clinical trial information: ChiCTR2200059204 .

OPAR: A Randomized Trial of Partial Breast Irradiation in Five Fractions Once Daily for Early Breast Cancer

Journal of Clinical Oncology Do-Hoon Kim, Valérie Théberge, Sameer Parpia et al. Feb 10, 2025 DOI: 10.1200/jco.24.00600

PURPOSE Previous studies suggest that external-beam partial breast irradiation (PBI) delivered twice a day can lead to increased adverse cosmesis (AC). The objective of our trial was to determine whether two regimens for PBI given once daily over 1 week resulted in acceptable AC to inform a phase III trial. METHODS Patients age ≥50 years with invasive breast cancer or ductal carcinoma in situ, ≤3 cm in size treated by lumpectomy with negative axillary nodes were randomly assigned to external-beam PBI of 30 Gy or 27.5 Gy, each given in five fractions once daily. The primary outcome was AC (fair or poor) by photographic assessment at 2 years. Secondary outcomes included AC assessed by nurse at 2 years, by patient self-assessment at 3 years, and late toxicity. On the basis of a 17% risk of AC with whole-breast irradiation, the upper bound of a two-sided 90% CI, 23% was set as the tolerance margin (OPAR, ClinicalTrials.gov identifier: NCT02637024 ). RESULTS In total, 142 patients were randomly assigned to 30 Gy and 139 to 27.5 Gy. The median follow-up was 5 years. The mean age was 65 years, and the mean tumor size was 1.2 cm. Both schedules met acceptability criteria by photographic assessment (AC, 12.1% [90% CI, 8.2 to 17.6] for 30 Gy and 15.2% [90% CI, 10.8 to 21.1] for 27.5 Gy) and by nurse assessment. AC by patient self-assessment exceeded the 90% CI for the 30 Gy regimen. At 5 years, 16 (11.3%, 90% CI, 7.6 to 16.4) patients treated with 30 Gy and eight (5.8%, 90% CI, 3.3 to 9.9) patients treated with 27.5 Gy were observed to have grade 2 or more late toxicity. CONCLUSION According to the study design, 30 Gy and 27.5 Gy resulted in acceptable cosmetic outcomes. In light of recent studies, a lower dose was chosen for the phase III trial.

High-power GeSn photodetector for 2-<i>μ</i>m RoF system

Applied Physics Letters Jinlai Cui, Jun Zheng, Xiangquan Liu et al. Feb 10, 2025 DOI: 10.1063/5.0250619

A radio-over-fiber (RoF) link simplifies the base station and network structure, adapting to the trends of high capacity and rapid development in modern communication. The development of 2-μm-band links improves the capacity of communication systems, which can solve future optical fiber capacity crises. In this work, a relaxed high-Sn-content GeSn absorption layer was grown on a Si substrate, and high-power GeSn photodetectors were fabricated. The photodetectors achieved a low dark current with a cutoff wavelength of about 2930 nm. The GeSn photodetectors had a saturated photocurrent of up to 70 mA operating in the 2-μm-wavelength range and a 3-dB bandwidth of approximately 1.6 GHz. The results provide a technical reference for the application of GeSn 2-μm detectors in RoF links.

Distinct water and phosphorus extraction patterns are key to maintaining the productivity of sorghum under drought and limited soil resources

Scientific Reports Sara Loftus, Anna M. Sauer, Eva M. Schneider et al. Feb 10, 2025 DOI: 10.1038/s41598-025-88705-x

Abstract Nutrient and water limitations contribute to yield losses in semi-arid regions. Therefore, crop rotations incorporating nitrogen-fixing legumes and drought-tolerant sorghum varieties offer a strategy to improve the utilization of scarce soil resources. Under semi-arid, field-like conditions, sorghum crop rotations with either cowpea pre-crop or fallow, including two early and three late maturing genotypes, were tested to identify stress adaptation traits of sorghum to water and phosphorus limitations. Morphological and physiological parameters were evaluated on a single-plant basis. Lower soil P content significantly delayed flowering compared to higher P levels. However, improved P availability arising from pre-crop residues reduced this effect. Mycorrhizal infection rates and root-to-shoot ratios were positively correlated with panicle N and P content at anthesis under low P conditions. Although drought significantly impacted yield, early maturing genotypes with the highest reduction in shoot biomass and reduced water use before flowering, could sustain yield production. Early-maturing genotypes characterized by high root-to-shoot ratios, rapid AMF establishment, and reduced water use before flowering exhibit a strong potential for maintaining yield and biomass production on nutrient-poor soils in semi-arid regions. Such genotypes conserve water before flowering and thus can alleviate post-flowering water stress, ensuring adequate P uptake despite low soil P availability.

Clinical outcomes in metastatic bladder cancer associated with mutations in Trithorax-group protein genes.

Journal of Clinical Oncology Mark Sikov, Galina Lagos, Sheldon L. Holder et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.835

835 Background: The Trithorax-group (TrxG) comprises a large family of multi-protein complexes that play a key role in epigenetic regulation, cell division and inflammatory response; mutations therefore have a potential role as biomarkers or treatment targets. Two crucial complexes in TrxG are COMPASS (histone methylation) and SWI/SNF (chromatin remodeling). Certain genes in these complexes have been implicated as tumor suppressors and oncogenes, respectively. In urothelial cancer, mutations have been associated with more aggressive tumor biology, an immune-dysregulated microenvironment, and worse clinical outcomes. However, research into the overall impact of mutations in these complexes, particularly in metastatic setting, is scarce. We hypothesized mutations would predict worse outcomes following treatment, specifically investigating metastatic urothelial carcinoma (mUC). Methods: We retrospectively reviewed data from 63 patients with mUC treated at Brown Health Cancer Institute with next generation sequencing available from tumor or ctDNA. Demographic, pathologic, treatment and response data were collected. The presence of somatic alterations in the COMPASS complex ( KDM6A, KMT2B/C/D, SETD1/2, EP300 ) and SWI/SNF complex ( SMARCA2/4, SMARCB1, SMARCC1/2, ARID1A/B, ARID2 ) genes were noted. Log rank tests were used to analyze differences in overall survival (OS) and progression free survival (PFS) stratified by mutation status and first line treatments received. All outcomes were censored as of 12/31/22. Results: Of the 63 patients, the majority were male (41, 65%), white (57, 90%), had a smoking history (41, 65%). Median age was 74 (± 9.5). 28 (44%) received first-line chemotherapy and 31 (49%) received immune checkpoint inhibitor (ICI) monotherapy. 3 (5%) died prior to treatment and 1 (2%) entered a clinical trial. 41 (65%) had a mutation in any investigated TrxG gene; most common were KMT2D (17, 27%) and KDM6A (14, 22%). Patients with mutations were more likely to be older (75 vs 70, p = 0.04); there was no statistically significant difference in sex, smoking history, race, or sites of metastasis. The presence of a mutation was not associated with OS in the full cohort (median 14 months vs 13, p = 0.63, HR = 0.86 [0.45 – 1.6]). In the subset of patients who received first line chemotherapy, mutation presence (17, 61%) was associated with improved OS (21 months vs 10, p = 0.015, HR = 0.26 [0.08 – 0.77]) and PFS (7.9 vs 3.8, p = 0.051, HR = 0.36 [0.13 – 1.0]). Among patients who received first line ICI, mutation presence (19, 61%) had a trend for reduced PFS, (4.3 months vs 17, p = 0.06, HR = 2.2 [0.96 – 5.0]). Conclusions: Mutations in COMPASS and SWI/SNF genes were common in patients with mUC and associated with improved outcomes with 1st line chemotherapy and inferior responses to ICIs. TrxG mutations hold potential as predictive biomarkers, and merits further exploration in larger datasets.

Clinical outcomes of stage IIA/IIB seminoma treated with radiotherapy and chemotherapy: Should regional therapy be considered the preferred treatment approach?

Journal of Clinical Oncology Rachel Glicksman, Di Maria Jiang, Philippe Bedard et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.629

629 Background: With the publication of the Surgery in Early Metastatic Seminoma Trial there has been increasing interest in the use of regional therapy as first line treatment (reserving systemic therapy for relapse) in patients with testicular seminoma with low volume with retroperitoneal lymphadenopathy. Herein, we sought to evaluate outcomes with both management approaches. Methods: A prospectively maintained single-institutional database was retrospectively queried for patients diagnosed between 1995-2016 with de novo clinical stage IIA/B (CSIIA/B) or who relapsed on surveillance (Rel-CSIIA/B) treated with radiotherapy or chemotherapy. All patients were reviewed by the multidisciplinary team; while the preferred management policy during this period was radiotherapy, all treatment decisions were individualized at the physician/patient level. Results: The median follow-up was 7.1 years (IQR 4.3-9.9). There were 153 patients: 67 had de novo CSIIA/B (IIA-32, IIB-35) and 86 patients had Rel-CSIIA/B seminoma (IIA-51, IIB-35). One hundred and twenty patients (78%) received radiotherapy (IIA-78, IIB-42) and 33 (22%) received platinum-based chemotherapy (IIA-5, IIB-28). Eleven patients (IIA- 9/78, IIB- 2/42) relapsed following radiotherapy and 1 patient (IIB) relapsed following chemotherapy, corresponding to 5-year relapse rates of 10% for radiotherapy and 3% for chemotherapy. All 12 patients who relapsed were treated successfully with salvage chemotherapy. Conclusions: Regional therapy in patients with testicular seminoma with low volume with retroperitoneal lymphadenopathy gives excellent treatment results – recognising that a small proportion of patients will need salvage chemotherapy for cure, thereby exposing these patients to the morbidity of two treatment strategies. Our results support the view that regional therapy is a reasonable treatment option in this setting and should be discussed with all patients.